A study published in Nature on August 6, 2025, found that lithium is the only metal significantly depleted in the prefrontal cortex of people with mild cognitive impairment and Alzheimer’s disease, based on post-mortem analysis of human brain tissue. The same research team showed that low-dose lithium orotate reversed memory deficits in mice, raising the question of whether restoring trace lithium levels could help protect memory in aging humans. The finding arrives as several earlier clinical trials already pointed toward cognitive benefits from subtherapeutic lithium doses, though the evidence remains incomplete and sometimes contradictory.
Brain Lithium Levels Are Lower in MCI and Alzheimer’s
The Aron et al. Nature paper used metallomic profiling to measure concentrations of multiple metals across post-mortem human brain samples. Of all the elements tested, lithium was the only one significantly reduced in the prefrontal cortex of individuals diagnosed with mild cognitive impairment, with even steeper declines in those who had progressed to Alzheimer’s disease. That pattern held after accounting for other metals and tissue variables, suggesting the deficit is specific rather than part of a broader mineral imbalance.
In the animal portion of the study, researchers administered low-dose lithium orotate to mice engineered to develop Alzheimer’s-like pathology. According to an NIH summary, the treated mice showed improved memory performance and reduced amyloid plaque burden compared to untreated controls. The lithium orotate formulation delivered the element at doses far below those used in psychiatric treatment for bipolar disorder, which matters because standard therapeutic lithium doses carry well-documented risks to kidney and thyroid function. The mouse results offer a plausible biological mechanism, but translating rodent memory improvements to human verbal recall requires a different kind of evidence.
Small Human Trials Show Stabilized Cognition
Two randomized controlled trials conducted before the Nature paper tested whether low-dose lithium could protect cognition in people already showing signs of decline. A double-blind study in people with amnestic mild cognitive impairment titrated lithium to subtherapeutic serum levels of 0.25 to 0.5 mmol/L. Over the treatment period, participants receiving lithium showed stabilized scores on the ADAS-Cog, a standardized cognitive assessment, while the placebo group continued to decline. That trial used general cognitive endpoints rather than isolating verbal memory specifically, which leaves a gap between the headline promise and the measured outcomes.
A separate randomized trial in Alzheimer’s tested an even smaller “microdose” of lithium and reported that treated patients experienced slower overall cognitive deterioration. Both trials were small, and neither was designed to measure verbal memory as a standalone domain using tools like the Rey Auditory Verbal Learning Test. The results are encouraging but limited: they show lithium can stabilize broad cognitive function at low doses without the side-effect burden of full psychiatric dosing, yet they stop short of proving that verbal memory, one of the earliest casualties of Alzheimer’s pathology, responds to lithium independently of other cognitive domains.
Drinking Water Studies Tell a Muddled Story
Beyond clinical trials, researchers have tried to test the lithium-cognition link by studying populations exposed to naturally occurring lithium in their tap water. A large Danish observational study, described in a JAMA Psychiatry report, analyzed 73,731 dementia cases alongside 733,653 controls and reported that higher lithium concentrations in drinking water were associated with lower dementia incidence. That finding generated significant interest because it suggested even trace environmental lithium exposure might be protective at a population level.
But a U.S.-based analysis told a different story. According to a separate study also in JAMA Psychiatry, the association between groundwater lithium and dementia diagnosis disappeared after adjusting for demographic factors and health care resources. The authors noted that regions can differ in socioeconomic conditions and access to care in ways that may confound ecological comparisons of lithium exposure and dementia rates. A systematic review of trace exposure confirmed this tension, noting that the ecological studies suffered from selection bias and inconsistent confounder control. The drinking water evidence, taken as a whole, cannot reliably separate lithium’s effect from the many other variables that differ across geographic regions.
What This Means for Memory and What It Does Not
The strongest version of the current evidence looks like this: lithium levels are lower in the brains of people diagnosed with mild cognitive impairment and Alzheimer’s disease, low-dose lithium reverses memory problems in mice, and small human trials show it can stabilize cognitive decline at doses well below those used in psychiatry. Each piece supports the idea that lithium plays a role in brain health, and the convergence across post-mortem tissue, animal models, and clinical trials is more persuasive than any single study would be on its own. Reporting from Nature News noted that the Aron et al. paper drew expert attention precisely because it connected the human tissue findings to a functional animal model in a single investigation.
At the same time, the gaps are substantial. The post-mortem data show correlation, not causation: lower lithium in the prefrontal cortex might contribute to neurodegeneration, or it might simply reflect downstream changes in damaged tissue. The mouse experiments demonstrate that supplementing lithium can improve memory in a highly controlled model, but Alzheimer’s disease in humans is more heterogeneous and unfolds over decades. And the human trials, while promising, are too small and too broad in their outcome measures to nail down whether verbal memory specifically is being preserved or whether lithium is exerting a more diffuse effect on global cognition. Without large, well-powered trials that focus on domain-level outcomes, it is premature to claim that restoring trace lithium levels will reliably protect word recall, story memory, or name-finding ability in older adults.
Safety, Self-Medication, and the Road Ahead
Any discussion of lithium and cognition has to grapple with safety. At psychiatric doses, lithium is an effective mood stabilizer but requires regular blood monitoring because of its narrow therapeutic window and potential toxicity to the kidneys and thyroid. Even at lower doses, the compound is pharmacologically active, and the line between “microdose” and “no effect” is not sharply drawn. A review of neuroprotective mechanisms emphasized that lithium influences multiple signaling pathways involved in cell survival and inflammation, which may underlie potential cognitive benefits but also means unexpected effects are possible outside controlled research settings.
For people worried about memory loss, the emerging data can be tempting enough to encourage experimentation with over-the-counter lithium supplements, including lithium orotate formulations similar to those used in the mouse studies. Yet supplement quality and labeling can vary, and the actual lithium content may not always match what is listed on the label. Authoritative health resources such as MedlinePlus caution that unsupervised lithium use can interact with blood pressure medications, diuretics, and nonsteroidal anti-inflammatory drugs, among others. Until larger human trials clarify which doses, if any, improve specific aspects of cognition with an acceptable safety profile, experts generally advise against self-medicating for memory protection.
Looking ahead, the most informative studies will likely combine several approaches: tracking lithium levels in living patients using advanced imaging or cerebrospinal fluid assays, running multi-year randomized trials that focus on early-stage cognitive changes, and integrating genetic or biomarker data to identify who might benefit most. Verbal memory tests will need to sit alongside broader cognitive batteries so researchers can tell whether any protective effect is targeted or global. For now, the story is intriguing but unfinished: lithium clearly matters to the aging brain, but whether carefully calibrated supplementation can meaningfully preserve the words and stories that anchor our identities remains an open question rather than a clinical recommendation.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
